Because tumors with high PLD1 expression exhibit relatively high gemcitabine resistance, we used subcutaneous patient-derived organoid (PDO)-based xenografts (PDOXs) and orthotopic mouse tumor models to determine whether Vu0155069 enhanced sensitivity to gemcitabine by reducing PLD1 activity. Here, PLD1 is linked to neoplasm.